Business
Gelesis to Present Full Data for Lead Candidate
Gelesis to Present Full Data for Lead Candidate.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 2651G PureTech Health PLC 05 November 2018 \n\n5 November 2018\n \nPureTech plc\n \nPureTech's Gelesis to Present Expanded Pivotal Data for Lead Product Candidate at ObesityWeek 2018\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced that its affiliate, Gelesis, will present expanded data from the pivotal study of Gelesis100, its lead investigational product candidate for weight loss. The data will be presented at ObesityWeek 2018, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Nashville, Tennessee, from 11-15 November 2018.\n \nEric Elenko, PhD, Chief of Research and Strategy at PureTech Health, said: \"We are looking forward to Gelesis' strong presence at ObesityWeek 2018, the preeminent forum that brings together world-renowned experts in obesity to share innovation and breakthroughs in science. The expanded data from the pivotal study of lead product candidate, Gelesis100, will provide additional insights around the potential for this exciting new approach to weight loss.\"\n \nThe full text announcement from Gelesis is as follows:\n \nGelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018\n \nBOSTON, Nov. 5, 2018 - Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced that the Company will deliver an oral presentation and three poster presentations at ObesityWeek 2018, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Nashville, Tennessee, from November 11-15, 2018. The presentations will share data from the pivotal study of Gelesis100, an oral, non-systemic approach to weight loss, including data regarding early predictors of clinically meaningful weight loss.\n \n\"We are pleased to be able to present key clinical data from the pivotal study of our lead investigational product for weight loss, Gelesis100,\" said Harry L. Leider, MD, MBA, FACPE, Chief Medical Officer of Gelesis. \"There is a tremendous need for new approaches to addres...